Zobrazeno 1 - 10
of 22
pro vyhledávání: '"R. Fesen"'
Autor:
J. Rho, S.-H. Park, R. Arendt, M. Matsuura, D. Milisavljevic, T. Temim, I. De Looze, W. P. Blair, A. Rest, O. Fox, A. P. Ravi, B.-C. Koo, M. Barlow, A. Burrows, R. Chevalier, G. Clayton, R. Fesen, C. Fransson, C. Fryer, H. L. Gomez, H.-T. Janka, F. Kirchschlager, J. M. Laming, S. Orlando, D. Patnaude, G. Pavlov, P. Plucinsky, B. Posselt, F. Priestley, J. Raymond, N. Sartorio, F. Schmidt, P. Slane, N. Smith, N. Sravan, J. Vink, K. Weil, J. Wheeler, S. C. Yoon
Publikováno v:
The Astrophysical Journal Letters, Vol 969, Iss 1, p L9 (2024)
We present JWST NIRCam (F356W and F444W filters) and MIRI (F770W) images and NIRSpec Integral Field Unit (IFU) spectroscopy of the young Galactic supernova remnant Cassiopeia A (Cas A) to probe the physical conditions for molecular CO formation and d
Externí odkaz:
https://doaj.org/article/016bc259901442d3a49e82bfea30349c
Autor:
Steven R, Deitcher, Mark R, Fesen, Paul M, Kiproff, Patricia A, Hill, Xin, Li, Edward R, McCluskey, Charles P, Semba
Publikováno v:
Journal of Clinical Oncology. 20:317-324
PURPOSE: To evaluate the safety and efficacy of alteplase (TPA) for restoring function to occluded central venous catheters (CVCs). PATIENTS AND METHODS: The study design was a phase III, open-label, single-arm multicenter trial. Subjects with occlud
Autor:
Kurt W. Kohn, Yves Pommier, Krishnamchari Raghavan, John K. Buolamwini, Mark R. Fesen, John N. Weinstein
Publikováno v:
Pharmaceutical Research. 13:1892-1895
Purpose. A QSAR study based on electrotopological state (E-state) indices was conducted for a series of flavone HIV-1 integrase inhibitors to guide drug design. Methods. E-state indices formulated to encode electronic and topological information for
Autor:
M. R. Fesen, Macki Kaloga, A. Mazumder, Heinz H. Pertz, Yves Pommier, Eckart Eich, Jutta Schulz
Publikováno v:
Journal of Medicinal Chemistry. 39:86-95
The natural dibenzylbutyrolactone type lignanolide (-)-arctigenin (2), an inhibitor of human immunodeficiency virus type-1 (HIV-1) replication in infected human cell systems, was found to suppress the integration of proviral DNA into the cellular DNA
Autor:
K. Raghavan, John K. Buolamwini, Mark R. Fesen, John N. Weinstein, Yves Pommier, Kurt W. Kohn
Publikováno v:
Journal of Medicinal Chemistry. 38:890-897
We present the results from a comparative molecular field analysis (CoMFA) of a set of flavone analogs that inhibit HIV-1 integrase-mediated cleavage (3'-processing step) and integration (strand transfer step) in vitro. The results indicate a strong
Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds
Autor:
Kurt W. Kohn, Mark R. Fesen, François Leteurtre, Yves Pommier, Satoshi Hiroguchi, Jessie Yung
Publikováno v:
Biochemical Pharmacology. 48:595-608
The inhibition of HIV-1 integrase by flavones and related compounds was investigated biochemically and by means of structure-activity relationships. Purified enzyme and synthetic oligonucleotides were used to assay for three reactions catalysed by in
Publikováno v:
Biochemistry. 32:8955-8962
Camptothecin-induced DNA photolesions were examined after UVA irradiation at 365 nm. DNA single-strand breaks were induced both in supercoiled and in relaxed SV40 DNA. In uniquely end-labeled human c-myc DNA, camptothecin-induced cleavage occurred ex
Autor:
T. R. Jun. Burke, Yves Pommier, A. M. Carothers, Mark R. Fesen, Jian Wang, Abhijit Mazumder, Dezider Grunberger, J. Driscoll, Kurt W. Kohn
Publikováno v:
ChemInform. 27
Autor:
Macki Kaloga, M. R. Fesen, A. Mazumder, Yves Pommier, Heinz H. Pertz, Jutta Schulz, Eckart Eich
Publikováno v:
ChemInform. 27
The natural dibenzylbutyrolactone type lignanolide (−)-arctigenin (2), an inhibitor of human immunodeficiency virus type-1 (HIV-1) replication in infected human cell systems, was found to suppress the integration of proviral DNA into the cellular D
Autor:
Veena Charu, Glen R. Justice, Denise Williams, Mark R. Fesen, Roger J. Waltzman, Christopher Croot
Publikováno v:
The oncologist. 10(8)
This is the first randomized, open-label, multicenter trial designed and powered to directly compare the hemoglobin (Hb) response to epoetin alfa (EPO), 40,000 U once weekly (QW), with that to darbepoetin alfa (DARB), 200 μ g every 2 weeks (Q2W), in